BVAX.F Stock Overview
A clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
BioVaxys Technology Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.039 |
| 52 Week High | CA$0.076 |
| 52 Week Low | CA$0.029 |
| Beta | -0.17 |
| 1 Month Change | -12.44% |
| 3 Month Change | -30.27% |
| 1 Year Change | -18.60% |
| 3 Year Change | -73.01% |
| 5 Year Change | n/a |
| Change since IPO | -86.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| BVAX.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -15.7% | 1.2% | -0.3% |
| 1Y | -18.6% | 1.1% | 20.4% |
Return vs Industry: BVAX.F underperformed the US Pharmaceuticals industry which returned 1.3% over the past year.
Return vs Market: BVAX.F underperformed the US Market which returned 22% over the past year.
Price Volatility
| BVAX.F volatility | |
|---|---|
| BVAX.F Average Weekly Movement | 14.3% |
| Pharmaceuticals Industry Average Movement | 10.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 18.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BVAX.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BVAX.F's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Chris Passin | biovaxys.com |
BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune-educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. Its product pipeline includes Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and for platinum resistant ovarian cancer; MVP-S +1 Keytruda that is in IIb clinical trial to treat lung cancer, bladder cancer, liver cancer, DLBCL, and ovarian cancer subpopulations; BVX-0918, a haptenized tumor cell vaccine for ovarian cancer; and DPX SurMAGE, which is in phase I clinical stage to treat the MAGE protein family member A9 in human cancers.
BioVaxys Technology Corp. Fundamentals Summary
| BVAX.F fundamental statistics | |
|---|---|
| Market cap | US$10.99m |
| Earnings (TTM) | -US$2.54m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.3x
P/E RatioIs BVAX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BVAX.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$3.63m |
| Earnings | -CA$3.63m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.013 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -32.6% |
How did BVAX.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 15:37 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/07/31 |
| Annual Earnings | 2023/10/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioVaxys Technology Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.